Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors

Nuvation Bio Inc. (NYSE:NUVB) is one of the best high short interest stocks with biggest upside potential. On January 27, Truist raised its price target on Nuvation Bio to $13 from $11 and maintained a Buy rating, citing the Ibtrozi franchise’s robust initial performance as part of a Q4 2025 earnings preview for the biotech sector. Despite seasonal challenges, the firm observed stronger-than-expected market uptake, which positions Ibtrozi as the preferred ROS1 agent over its competitors.

Earlier on January 21, RBC Capital analyst Leonid Timashev raised the price target for Nuvation Bio to $12 from $9 with an Outperform rating. This adjustment followed meetings with management teams, leading the firm to update its financial models for several companies in the biotech sector.

Truist Highlights Nuvation Bio's (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors

On January 12, H.C. Wainwright lowered its price target for Nuvation Bio Inc. (NYSE:NUVB) to $17 from $18 while maintaining a Buy rating. The firm noted that the company’s preliminary Q4 Ibtrozi net product revenue of ~$15.7 million aligned with its expectations.

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company that develops therapeutic candidates for oncology.

While we acknowledge the potential of NUVB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NUVB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.